5 things to know about LAGEVRIO® (molnupiravir) – an oral antiviral treatment for COVID-19

LAGEVRIO® (molnupiravir) has provisional approval for the treatment of adults with COVID-19 who do not require initiation of oxygen due to COVID-19 and who are at increased risk for hospitalisation or death. The decision to approve this indication was based on efficacy and safety data from a Phase 3 trial. Continued approval of this indication

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous ‘Extremely honoured’: Pharmacist director’s hard work commended
Next Wastewater reveals lower drug use